Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Merus

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading.

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

4 A-Rated Biotech Stocks Sparking Investor Interest

The biotech industry is rapidly evolving thanks to the surging biopharma M&A activity and incorporation of new technological trends like AI and gene editing. Given this backdrop, quality biotech stocks Gilead Sciences (GILD), Equillium (EQ), Incyte Corporation (INCY), and Jazz Pharmaceuticals plc (JAZZ), rated A (Strong Buy) overall in our…

Needham Says Merus' ASCO Update On Zeno 'Positive'

Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer.

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Corporation (NASDAQ: INCY) is

Organisations

Gilead Sciences Inc

Jazz Pharmaceuticals plc

Incyte Corporation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

332,916 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play